Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

Gastroesophageal symptoms significantly impact methotrexate dosages and disease activity among patients with RA.

TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...

A new study has discovered the reason why men tend to sustain more heart muscle damage following a heart attack than women: ...

TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% ...

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

man.ac.uk Background: There is a wide variation in responses to standard disease modifying antirheumatic drug (DMARD) treatment in rheumatoid arthritis (RA). Whether multidrug resistance, failure to ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

Goniotomy may be a first-line approach to treating pediatric patients with glaucoma secondary to uveitis, with improvements ...

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...